Celecoxib still on the market: But for whose benefit?

Prescrire International

Volumn 14, Issue 79, 2005, Pages 177-178

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PLACEBO; ROFECOXIB; SULFONAMIDE; VALDECOXIB;

ADVISORY COMMITTEE; ALZHEIMER DISEASE; ANALGESIA; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ARTERY DISEASE; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLON POLYP; CROSS REACTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUROPE; EXFOLIATIVE DERMATITIS; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MORTALITY; POSTMARKETING SURVEILLANCE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; THROMBOCYTE AGGREGATION; THROMBOSIS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT CONTRAINDICATION; UNITED STATES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DRUG AND NARCOTIC CONTROL; EUROPE; HEALTH CARE SECTOR; HUMANS; PYRAZOLES; SAFETY; SULFONAMIDES; UNITED STATES;

EID: 27144497666     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Prescrire Rédaction "rofécoxib: arrêt de commercialisation" Rev Prescrire 2004; 24 (255): 748.
2. Prescrire Editorial Staff "Cox-2 inhibitors: still no decisive action" Prescrire Int 2005; 14 (77): 102.
3. Prescrire Rédaction "Coxibs, suite: retrait du valdécoxib" Rev Prescrire 2005; 25 (261): 350.
4. US Food and Drug Administration "FDA public health advisory. FDA announces important changes and additional warnings for Cox-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs)" 7 April 2005. Website http://www.fda.gov accessed on 23 May 2005.
5. European Medicines Agency "Public Statement - European Medicines Agency announces regulatory action on Cox-2 inhibitors". Website http://www.emea.eu.int accessed on 25 May 2005.
6. Prescrire Editorial Staff "Celecoxib" Prescrire Int 2001; 10 (52): 46-49.
7. Prescrire Editorial Staff "Coxibs: we want our money back!" Prescrire Int 2004, 13 (74): 236.
8. Prescrire Editorial Staff "Celecoxib and the CLASS trial" Prescrire Int 2002; 11 (62): 190-191.
9. Prescrire Editorial Staff "Coxibs: no better then other NSAIDs" Prescrire Int 2004; 13 (74): 226.
10. Prescrire Rédaction "Rofécoxib: arrêt de commercialisation (suite)" Rev Prescrire 2004, 24 (256): 835.
11. Prescrire Editorial Staff "Coxibs: cardiovascular adverse effects" Prescrire Int 2002; 11 (62): 181-182.
12. Prescrire Rédaction "Coxibs et risques cardiovasculaires (suite)" Rev Prescrire 2005; 25 (258): 109.
13. US Food and Drug Administration "Memorandum. Analysis and recommendations for Agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk" 6 April 2005. Website http://www.fda.gov accessed on 5 May 2005.
14. "TMT Review. Cardiovascular Safety of Celebrex" 12 January 2005. Website http://www.fda.gov consulted on 5 April 2005.
15. US Food and Drug Administration "Review of NDA21042/s030 (update of cardiovascular thrombotic events in Alzheimer's studies 078 et 091). Website http://www.fda.gov accessed on 3 March 2005.
16. Prescrire Rédaction "Coxibs et chocs anaphylactiques" Rev Prescrire 2003; 23 (236): 111.
17. "Celebrexo". In French datasheet compendium French datasheet compendium: "Dictionnaire Vidal" Vidal, Issy-les-Moulineaux 2005: 343-344.
18. European Medicines Agency "Press release: European medicines agency concludes action on COX-2 inhibitors + Questions and answers on COX-2 inhibitors" 27 June 2005. Website http://www.emea.eu.int accessed on 7 July 2005.